Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Pharma 5.0
Company News
Events
Directory
Search
Close search
Home
Company
Flamel Technologies
Flamel Technologies
X
LinkedIn
Trending Articles
Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success
Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for...
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
ChargePoint invest in a single-use manufacturing facility to expand product line
The single-use manufacturing facility will become fully operational in June 2024, and will support the company's trio of liquid and powder transfer devices
COVID-19 still a significant risk for the immunocompromised, study finds
AstraZeneca's INFORM study highlights the persistent danger of COVID-19 for the immunocompromised despite the vaccination scheme
Broughton receives flexible scope ISO 17025 accreditation
New certification allows accreditation without prior approval
Upcoming event
ASGCT Annual Meeting 2024
7-11 May, 2024 | Meeting | Portland, OR
See all
Related Content
Manufacturing
Flamel Technologies makes two new appointments
SVP of Quality and Regulatory Affairs and VP of Business and Corporate Development join the company
Manufacturing
Recipharm acquires Flamel Technologies facility for €10.6m and extends development services in France
Also invests €10.5m in Flamel stock
You need to be a subscriber to read this article.
Click here
to find out more.
Drug Delivery
Helping the delivery of biotech-based therapies
Modern biotech-derived medicines require new methods to aid targeted delivery. Dr Sarah Houlton, looks at some of the novel nano-based technologies that are getting results
Drug Delivery
Flamel Technologies acquires Eclat Pharmaceuticals
Aims to become a more vertically integrated drug development company
Ingredients
Flamel and Digna Biotech in multiple product agreement
Three initial Digna products have been identified for development
Subscribe now